Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

Annals of Oncology

Volumn 16, Issue 10, 2005, Pages 1632-1638

  Banerjee, S ^a   Smith, Ian E ^a   Folkerd, L ^a   Iqbal, J ^a   Barker, P ^b   Dowsett, M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Anastrozole; Bone; Breast cancer; Lipids; Neoadjuvant; Tamoxifen

Indexed keywords

ANASTROZOLE; CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NEEDLE BIOPSY; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BONE RESORPTION; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 25644458142     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi322     Document Type: Article

References (30)

1. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-1204.
2. Rogers A, Saleh G, Hannon RA et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 4470-4475.
3. Love RR, Wiebe DA, Feyzi JM et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534-1539.
4. Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-856.
5. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998; 83: 1158-1162.
6. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-2442.
7. Smith IE, Dowsett M, Ebbs S et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: The IMPACT multicentre double-blind randomised trial. J Clin Oncol 2005; in press.
8. Dowsett M, Goss PE, Powles TJ et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Res 1987; 47: 1957-1961.
9. Morales M, Santana N, Soria A et al. Effects of tamoxifen on serum lipid arid apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat 1996; 40: 265-270.
10. Wojtacki J, Kruszewski W, Sliwinska M et al. Effect of non-steroidal aromatase inhibitors (AI) on serum lipid profile in patients with breast cancer. Preliminary report. Eur J Cancer 2000; 36: S5 (Abstr 146).
11. Bonneterie J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757.
12. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
13. Dewar J, Nabholtz J, Bonneterre J, Buzdar AU. The effect of anastrozole (Arimidex) on serum lipids-data from a randomised comparison of anastrozole versus tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 2000; 64 (Suppl): S51 (Abstr 164).
14. Sawada S, Sato K, Kusuhara M et al. Effect of anastrozole and tamoxiten on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncologica 2005; 44: 134-144.
15. Wojtacki J, Lesniewski-Kmak K, Pawlak W et al. Anastrozole therapy and lipid profile: An update. Euro J Cancer 2004; 2 (Suppl 3): 142 (Abstr 297).
16. Wojtacki J, Lesniewski-Kmak K, Piotrowska M et al. Effect of anastrozole on serum levels of apolipoprotein A-I and B in patients with early breast cancer: Additional data on lack of atherogenic properties. Breast Cancer Res Treat 2004; 88 (Suppl 1): S238 (Abstr 6053).
17. Costa LA, Kopreski MS, Demers LM et al. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma. Cancer 1999; 85: 100-103.
18. Harper-Wynne CL, Sacks NP, Shenton K et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002; 20: 1026-1035.
19. Atalay G, Dirix L, Biganzoli L et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004; 15: 211-217.
20. Kataja V, Hietanen P, Joensuu H et al. The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer - a randomised study. Breast Cancer Res Treat 2002; 76 (Suppl 1): S156 (Abstr 634).
21. Harper-Wynne C, Ross G, Sacks, N et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002; 11: 614-621.
22. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
23. Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998; 9: 639-645.
24. Elisaf MS, Bairaktari ET, Nicolaides C et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37: 1510-1513.
25. BIG 1-98 Collaborative Group, BIG 1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. The Breast 2005; 14 (Suppl 1): S3 (Abstr S4).
26. Eastell R, Adams J. Results of the 'Arimidex' (anastrozole, A), tamoxifen (T), alone or in combination (C) (ATAC) trial: Effects on bone mineral density (BMD) and bone turnover (ATAC Trialists' Group). Ann Oncol 2002; 13 (Suppl 5): 32 (Abstr 113).
27. Howell A. Effect of anastrozole on bone mineral density: 2-year results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 2003; 82 (Suppl 1): S27 (Abstr 129).
28. Sypniewska G, Chodakowska-Akolinska G. Bone turnover markers and estradiol level in postmenopausal women. Clin Chem Lab Med 2000; 38: 1115-1119.
29. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women completing ≥5 years (yrs) of adjuvant tamoxifen: NCIC CTG MA.17B. Breast Cancer Res Treat 2004; 88 (Suppl 1): S36 (Abstr 404).
30. Coleman RE, Banks LM, Hall E et al. Intergroup Exemestane Study: 1 year results of the bone sub-protocol. Breast Cancer Res Treat 2004; 88 (Suppl 1): S35 (Abstr 401).